Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $185,460.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the sale, the chief technology officer now directly owns 121,503 shares in the company, valued at $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $17.24 on Thursday. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -11.27 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52 week low of $7.38 and a 52 week high of $18.97. The company has a 50-day simple moving average of $16.74 and a 200 day simple moving average of $15.28.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNTA. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Atria Investments Inc boosted its holdings in Centessa Pharmaceuticals by 7.0% in the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after purchasing an additional 5,316 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Centessa Pharmaceuticals during the third quarter worth approximately $187,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CNTA has been the topic of a number of research analyst reports. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.